{{.infobox .infobox-gene}}
| Symbol | MS4A1 |
| Full Name | Membrane Spanning 4-Domains A1 (CD20) |
| Chromosome | 11q12.2 |
| NCBI Gene ID | 931 |
| OMIM | 112210 |
| Ensembl ID | ENSG00000156738 |
| UniProt ID | P08581 |
| Aliases | CD20, Bp35, LEU-16 |
| Associated Diseases | AD, MS, CLL, B cell lymphoma |
MS4A1 (Membrane Spanning 4-Domains A1), commonly known as CD20, is a member of the membrane-spanning 4A gene family. CD20 is a heavily glycosylated cell surface protein expressed primarily on B lymphocytes, where it plays essential roles in B cell activation, proliferation, and calcium influx[1]. Originally identified as a B cell-specific marker, CD20 has become one of the most successful therapeutic targets in hematology, with monoclonal antibodies like rituximab revolutionizing the treatment of B cell malignancies and autoimmune disorders.
However, emerging research has revealed that members of the MS4A gene family, including MS4A1, are expressed in the central nervous system and may play roles in neurodegenerative disease pathogenesis. Genome-wide association studies (GWAS) have consistently implicated the MS4A gene cluster on chromosome 11q12.1 in Alzheimer's disease risk, suggesting roles for these proteins in neuroinflammation, microglial function, and possibly amyloid processing[2][3][4].
MS4A1 is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
The MS4A1 gene is located on chromosome 11q12.2 and consists of 13 exons encoding a 297-amino acid glycoprotein. CD20 is a member of the MS4A family, which includes at least 15 related genes clustered on chromosome 11[1:1].
Key structural features include:
The protein topology distinguishes MS4A family members from typical receptor proteins:
Extracellular N-terminus → TM1 → Loop → TM2 → Loop → TM3 → Loop → TM4 → C-terminus cytoplasm
In B lymphocytes, CD20 serves critical functions[1:2]:
B cell receptor complex: CD20 associates with the B cell receptor (BCR) complex and modulates its signaling. Unlike most B cell surface proteins, CD20 is not shed or internalized upon activation.
Calcium homeostasis: CD20 forms calcium channels in the plasma membrane, enabling calcium influx that is essential for B cell activation and proliferation.
Cell cycle regulation: CD20 expression peaks during the G1/S transition of the cell cycle, suggesting roles in cell proliferation.
Costimulatory signaling: CD20 provides costimulatory signals that enhance BCR-mediated activation.
CD20 operates through several molecular mechanisms:
CD20 is expressed primarily in the B cell lineage:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Pro-B cells | Low | Early developmental stage |
| Pre-B cells | High | Beginning of CD20 expression |
| Immature B cells | Very High | Peak expression |
| Mature B cells | High | Peripheral blood, lymph nodes |
| Plasma cells | Negative | Terminally differentiated |
| Memory B cells | High | Antigen-experienced cells |
Interestingly, MS4A genes are expressed in the brain[5][6]:
The functional significance of MS4A expression in the CNS is an active area of research, particularly regarding its role in microglial function and neuroinflammation.
The MS4A gene cluster (including MS4A4E and MS4A6A is one of the most consistently replicated genetic loci in AD GWAS[2:1][3:1][4:1]. Proposed mechanisms include:
Microglial function: MS4A proteins are expressed in microglia, which play critical roles in amyloid clearance and neuroinflammation. Variants affecting MS4A expression could alter microglial responses to amyloid pathology.
Immune regulation: Altered immune function through MS4A variants may affect the brain's inflammatory response to amyloid and tau pathology.
Lipid metabolism: Some MS4A proteins are involved in lipid transport and metabolism, which is relevant given the lipid alterations observed in AD brains.
TREM2 interaction: The MS4A cluster may interact with TREM2, another major AD risk gene expressed in microglia[7].
CD20 is a well-established therapeutic target in multiple sclerosis[8][9]:
B cell depletion therapy: Anti-CD20 antibodies (rituximab, ocrelizumab, ofatumumab) depleting B cells have shown remarkable efficacy in MS.
Clinical trials: Ocrelizumab was the first anti-CD20 therapy approved for both primary progressive and relapsing forms of MS.
Mechanisms: B cell depletion likely works through multiple mechanisms:
CD20 is a critical marker and therapeutic target in:
The success of anti-CD20 monoclonal antibodies has made CD20 one of the most studied therapeutic targets in oncology.
GWAS have identified multiple MS4A locus variants associated with AD risk:
| SNP | Gene | Effect | Notes |
|---|---|---|---|
| rs6102059 | MS4A4E/MS4A6A | Protective | Associated with reduced risk |
| rs1562990 | MS4A4E | Risk | Increased risk |
| rs6100320 | MS4A6A | Effect | Alters expression |
| rs4837535 | MS4A4A | Effect | Common variant |
These variants likely affect:
Several therapeutic antibodies target CD20:
| Drug | Type | Approval Status | Indications |
|---|---|---|---|
| Rituximab | Chimeric IgG1 | Approved | NHL, CLL, RA |
| Ofatumumab | Human IgG1 | Approved | CLL, MS |
| Ocrelizumab | Humanized IgG1 | Approved | MS |
| Obinutuzumab | Humanized IgG2 | Approved | CLL |
Anti-CD20 antibodies work through multiple mechanisms:
The success of B cell depletion in MS raises questions about similar approaches in AD:
Clinical trials exploring this approach are underway.
The MS4A family includes multiple genes with diverse functions[1:3]:
| Gene | Expression | Function |
|---|---|---|
| MS4A1 (CD20) | B cells | B cell activation |
| MS4A2 (FcεRIβ) | Mast cells, basophils | IgE receptor subunit |
| MS4A3 (HTm4) | Hematopoietic cells | Cell cycle regulation |
| MS4A4E | Brain, immune cells | Unknown |
| MS4A6A | Brain, immune cells | Unknown |
| MS4A7 | Various tissues | Unknown |
| MS4A12 | Intestine | Unknown |
The function of many MS4A family members remains poorly characterized, particularly in the brain.
MS4A family genes show varying conservation:
| Species | MS4A1 Ortholog | Notes |
|---|---|---|
| Human | MS4A1 | 100% identity |
| Mouse | Ms4a1 | 87% similarity |
| Rat | Ms4a1 | 86% similarity |
| Zebrafish | ms4a1 | Lower conservation |
Mouse models: Knockout mice have been used to study CD20 function.
In vitro systems: Human B cell lines, primary B cells, and engineered cell lines.
Blasius et al. MS4A family - structure and function. Trends Immunol. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Hollingworth et al. Common variants in MS4A4E and MS4A6A contribute to Alzheimer's disease susceptibility. Nat Genet. 2011. ↩︎ ↩︎
Karch et al. The MS4A gene cluster influences Alzheimer's disease risk. Mol Psychiatry. 2012. ↩︎ ↩︎
Lambert et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013. ↩︎ ↩︎
Sutherland et al. MS4A expression in the brain. J Neurosci Res. 2011. ↩︎
Rutherford et al. MS4A genes in neurodegenerative disease. Neurobiol Aging. 2018. ↩︎
Demontell et al. TREM2 and MS4A variants in Alzheimer's disease. J Mol Neurosci. 2017. ↩︎
Feinstein et al. B cells in multiple sclerosis. Nat Rev Neurol. 2015. ↩︎
Cruz et al. Neurol Neuroimmunol Neuroinflamm. 2018. ↩︎